

ALLIA.143A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Zaghouani)	Group Art Unit 1644
)	
Appl. No.	:	08/779,767)	I hereby certify that this cor
)	all marked attachments are
Filed	:	January 7, 1997)	with the United States Po
)	Express Mail # E1879045
)	envelope addressed to: C
For	:	Compounds, Compositions and)	Patents and Trademarks, V
		Methods for the Endocytic)	20231, on
		Presentation of Immunosuppressive)	
		Factors)	<u>April 16, 200</u>
Examiner	:	P. Nolan)	<u>Nikki Weaver</u>
)	Nikki Weaver

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as Express Mail # FL879045042 US in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231. on

April 16, 2002

'nikk: weave

Nikki Weaver

REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents
Box RCE
Washington, D.C. 20231

Dear Sir:

Applicant is hereby filing a Request for Continued Examination ("RCE"). Prosecution of the above entitled application is currently closed in that a final Office Action was received dated October 21, 2002. Applicant did file an amendment on December 19, 2002 (within two months of the date of the Office Action) in response to the Office Action. However, the wrong serial number was inadvertently added to the amendment (09/779,767 instead of 08/779,767) and apparently the amendment has not been received by the Examiner and thus has not been entered. Applicant is furnishing a copy of the response and postcard confirming that it was in fact filed and received by the Patent Office.

For this reason, Applicant is NOT filing the RCE with a three month extension of time in that an extension of time should not be required. However, applicant's attorney has authorized the payment of extension fees in the transmittal and in this Request for Continued Examination should payment of extension fees be determined as necessary to keep the application from becoming abandoned. Applicant has also authorized payment of the RCE fee.

01 11008
FIVE
2801 BVS

#49/17
goiga
4-29-3

ALLIA.143A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Zaghouni, H.)	Group Art Unit 1644
Appl. No.	:	09/779,767)	
Filed	:	January 7, 1997)	
For	:	Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors)	
Examiner	:	P. Nolan)	

I hereby certify that this correspondence and
all marked attachments are being deposited
with the United States Postal Service as first
class mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Washington, D.C. 20231, on

12/19/2002
Christine Hughey
Christine Hughey

AMENDMENT AND RESPONSE TO OFFICE ACTION

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated October 21, 2002, applicant submits the following
response:

In the Claims:

Please amend claim 66 as follows:

#1
66. (Six times amended) A composition comprising an immunoglobulin or a portion thereof linked
to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of
binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor
antagonist, said composition having the property of being endocytosed by cells bearing said Fc
receptor and processed by the cells to present said T cell receptor antagonist in association with
endogenous MHC Class II molecules, thereby preventing activation of autoreactive T cells *in vivo*.